KRAS and prostate neoplasm: For example, the G12, G13, Q61 and A146 positions of KRAS accounted for most KRAS SNVs in both common and rare scenarios (lung non-small-cell tumors: 568/586 mutations; prostate tumors: 12/17 mutations; gliomas: 11/15), and the V600E mutation accounted for the plurality of BRAF SNVs in common and rare scenarios despite each gene having dozens of known activating SNVs (52 and 71, respectively).